Abstract
Purpose
Invasive lobular carcinoma (ILC) of the breast has unique clinicopathologic characteristics, compared to invasive ductal carcinoma. The role of the 21-gene Recurrence Score (RS) has not been clearly defined for ILC. We sought to determine the prognostic value of RS and the impact of adjuvant chemotherapy on long-term survival in patients with ILC.
Methods
Utilizing the Surveillance, Epidemiology and End Results database from 2004 to 2013, we identified records of women aged 18–74 years, diagnosed with estrogen receptor (ER)-positive ILC (stage I to III) with RS available. We categorized patients into risk groups based on the traditional RS cutoffs and into those of the Trial Assigning Individualized Options for Treatment (TAILORx). Five-year breast cancer-specific survival (BCSS) was analyzed using the Kaplan–Meier method and Cox proportional hazards models.
Results
Of the 7316 women included, 21% were in the low-risk; 71%, intermediate-risk; and 8%, high-risk groups as per TAILORx RS cutoffs. The 5-year BCSS was 99% in the low-risk, 99% in the intermediate-risk, and 96% in the high-risk groups. A high-risk RS as per TAILORx cutoff was independently associated with increased mortality (hazard ratio [HR] of death 2.37, 95% confidence interval [CI] 1.14–4.95) when compared to a low-risk RS. In both the high-risk and intermediate-risk groups, adjuvant chemotherapy was not significantly associated with the HR of death (high-risk, HR 1.14, 95% CI 0.55–2.38; intermediate-risk, HR 1.08, 95% CI 0.62–1.87).
Conclusion
For patients with ER-positive ILC, 8% were in the high-risk and 72% were in the intermediate-risk groups as per the TAILORx RS cutoffs. In the high-risk group, the RS predicted a lower 5-year BCSS. Adjuvant chemotherapy did not seem to confer a survival benefit for either the intermediate- or the high-risk cohorts.
Abbreviations
- BCSS:
-
Breast cancer-specific survival
- CI:
-
Confidence interval
- ER:
-
Estrogen receptor
- HER:
-
Human epidermal growth factor receptor
- HR:
-
Hazard ratio
- IDC:
-
Invasive ductal carcinoma
- ILC:
-
Invasive lobular carcinoma
- OS:
-
Overall survival
- PR:
-
Progesterone receptor
- RS:
-
Recurrence score
- SEER:
-
Surveillance, epidemiology, and end results
- TAILORx:
-
Trial assigning individualized options for treatment
References
Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826. doi:10.1056/NEJMoa041588
Győrffy B, Hatzis C, Sanft T et al (2015) Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res Treat 17:11. doi:10.1186/s13058-015-0514-2
Mamounas EP, Tang G, Fisher B et al (2010) Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677–1683. doi:10.1200/JCO.2009.23.7610
Sparano JA, Gray RJ, Makower DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:150927220039001. doi:10.1056/NEJMoa1510764
Gradishar W, Anderson B, Balassanian R et al (2016) Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14:324–354. doi:10.1136/bmj.324.7334.410
Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312. doi:10.1200/JCO.2007.14.2364
Rakha EA, El-Sayed ME, Powe DG et al (2008) Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 44:73–83. doi:10.1016/j.ejca.2007.10.009
Rakha EA, Ellis IO (2010) Lobular breast carcinoma and its variants. Semin Diagn Pathol 27:49–61. doi:10.1053/j.semdp.2009.12.009
Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506–519. doi:10.1016/j.cell.2015.09.033
Desmedt C, Zoppoli G, Gundem G et al (2016) Genomic characterization of primary invasive lobular breast cancer. J Clin Oncol 34:1872–1880. doi:10.1200/JCO.2015.64.0334
Bertucci F, Orsetti B, Nègre V et al (2008) Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 27:5359–5372. doi:10.1038/onc.2008.158
Delpech Y, Coutant C, Hsu L et al (2013) Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 108:285–291
Truin W, Vugts G, Roumen RMH et al (2016) Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol 23:51–57. doi:10.1245/s10434-015-4603-3
Marmor S, Hui JYC, Huang JL et al (2017) Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer. doi:10.1002/cncr.30699
Truin W, Voogd AC, Vreugdenhil G et al (2012) Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann Oncol 23:2859–2865. doi:10.1093/annonc/mds180
Felts JL, Zhu J, Han B et al (2017) An analysis of Oncotype DX recurrence scores and clinicopathologic characteristics in invasive lobular breast cancer. Breast J 30. Accessed 2/21/2017. doi: 10.1111/tbj.12751
Tsai ML, Lillemoe TJ, Finkelstein MJ et al (2016) Utility of oncotype DX risk assessment in patients with invasive lobular carcinoma. Clin Breast Cancer 16:45–50. doi:10.1016/j.clbc.2015.08.001
Siegelmann-Danieli N, Silverman B, Zick A et al (2013) The impact of the Oncotype DX recurrence score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi healthcare services experience with a unified testing policy. Ecancermedicalscience 7:1–10. doi:10.3332/ecancer.2013.380
Kelly CM, Krishnamurthy S, Bianchini G et al (2010) Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 116:5161–5167. doi:10.1002/cncr.25269
Tsai ML, Lillemoe TJ, Finkelstein MJ et al (2016) Utility of oncotype DX risk assessment in patients with invasive lobular carcinoma. Clin Breast Cancer 16:45–50. doi:10.1016/j.clbc.2015.08.001
Fisher B, Dignam J, Wolmark N et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673–1682. doi:10.1093/jnci/89.22.1673
Barroso-Sousa R, Metzger-Filho O (2016) Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Therap Adv Med Oncol 8:261–266. doi:10.1177/1758834016644156
Acknowledgments
The authors would like to thank Dr. Mary Knatterud for her assistance in editing this manuscript. Dr. Todd Tuttle reports a potential conflict of interest in holding an advisory board position for Genomic Health. There are no other conflicts of interest to disclose.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kizy, S., Huang, J.L., Marmor, S. et al. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Res Treat 165, 757–763 (2017). https://doi.org/10.1007/s10549-017-4355-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4355-9